17-Dec-2021 | Facts and Factors
“Ataxia Market By Disease Type (Idiopathic, Acquired Ataxia, and Genetic Ataxia), By Treatment Type (Speech Therapy, Physical Therapy, Pharmacotherapy, and Others), and By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2021–2026” states that the global demand for the ataxia market in 2020 was approximately USD 29,401.1 Million. The market is likely to grow at a CAGR of 10.2% and is anticipated to reach around 46,000.8 Million by 2026.
Ataxia is a group of degenerative neurological disorders, which have an effect on the coordination as well as movement center of the brain (cerebellum). The patient that suffers from ataxia has trouble maintaining balance or coordination, swallowing, and speech, and it might develop at any age group. Also, it is progressive in nature, that it gets worse with time. On the basis of the cause, the ataxia is segmented into three types that are idiopathic ataxia, genetic ataxia, and acquired ataxia. Various symptoms regarding ataxia comprise vision problems, decreasing coordination, loss of fine motor skills, trouble in walking, muscle tremors, slurred speech, and impaired balance with frequent falls, and others.
The growth of the ataxia is driven by key factors like the growing ataxia cases, several technological advancements in pharmacotherapy for providing treatment against the symptoms of ataxia, and a constantly improving rate of diagnosis. Moreover, the expanding count of government programs for rising awareness related to the ataxia is likely to fuel the market growth. Also, wide research and development goings-on with the pipeline drugs are responsible for the market expansion. Additionally, the rising support by many organizations is expected to propel the global ataxia market in the coming years.
However, the current expiry of some drugs to give treatment against symptomatic ataxia along with the lack of product approval against the ataxia treatment are some restraining factors that can slow down the ataxia market growth during the forecast period.
Geographically, the ataxia market has been classified into Europe, North America, Asia-Pacific, the Middle East, and Africa, and Latin America. North America is leading the global market of ataxia in terms of the region with high revenue. The high growth in this regional market can be attributed to the numerous supports from organizations for patient diagnosis and treatment, the rise in government funding for research goings-on, and the increasing prevalence of ataxia in the region.
The region of Asia-Pacific is expected to be an extremely beneficial market for ataxia treatment in the forthcoming years. Factors attributing to the growth of this region include the high patient population base with genetic strains of ataxia, the government initiatives to minimize such disorders, and the growing awareness concerning ataxia in this region.
Pfizer Inc., Larimar Therapeutics Inc., Acorda Therapeutics, Sanofi, Merck & Co. Inc., Allergan, Cellectis SA, Intellia Therapeutics Inc., GlaxoSmithKline plc, Capsida Biotherapeutics Inc., CRISPR Therapeutics, Editas Medicine, Healx, bluebird bio Inc., HCellectis SA, Lundbeck A/S, and Bio-Techne are several market players covered in the global ataxia market. Moreover, novel product launches, strategic collaborations, geographical growth, acquisitions, product approvals, mergers, and partnerships are different strategies used by major market players to expand growth avenues in the market.
Browse the full “Ataxia Market By Disease Type (Idiopathic, Acquired Ataxia, and Genetic Ataxia), By Treatment Type (Speech Therapy, Physical Therapy, Pharmacotherapy, and Others), and By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026” report at https://www.fnfresearch.com/ataxia-market
This report segments the global ataxia market as follows:
Global Ataxia Market: By Disease Type
- Idiopathic
- Acquired Ataxia
- Genetic Ataxia
Global Ataxia Market: By Treatment Type
- Speech Therapy
- Physical Therapy
- Pharmacotherapy
- Others
Global Ataxia Market: By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global Ataxia Market: Regional Segmentation Analysis
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
